Lobe Sciences Announces Share Consolidation

3 years ago

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company")…

NextGen Healthcare Named No. 1 Ambulatory EHR/PM Solution by Black Book Research for Fifth Consecutive Year

3 years ago

Clients Recognize Integration, Scalability and Innovation Strengths ATLANTA--(BUSINESS WIRE)--$NXGN #NextGenHealthcare--NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based…

RemSleep Holdings Inc. Issues a Letter from the CEO

3 years ago

Tampa, FL, June 06, 2022 (GLOBE NEWSWIRE) -- RemSleep Holdings Inc (OTC PINK: RMSL), a medical device manufacturer dedicated to…

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

3 years ago

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective…

UPDATE — Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th

3 years ago

Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ETNEW YORK, NY, June 06, 2022 (GLOBE NEWSWIRE) --…

SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer

3 years ago

SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a…

Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business

3 years ago

-- Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest…

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

3 years ago

-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety…

WIMI Hologram Academy: The Application of AR in Education and Its Prospects

3 years ago

HONG KONG, June 06, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,…

Treosulfan Pivotal Study Results Published

3 years ago

Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall survival superior after treosulfan compared…